Company Overview and News
SHANGHAI China is set to add more than 300 new and traditional drugs to its list of medicines the state will help patients pay for, the first change in more than seven years that will boost treatments for cancer, kidney disease, hepatitis and haemophilia.
SHANGHAI: China is set to add more than 300 new and traditional drugs to its list of medicines the state will help patients pay for, the first change in more than seven years that will boost treatments for cancer, kidney disease, hepatitis and haemophilia.
The Directors of JPMorgan Chinese Investment Trust plc announce the Company's results for the year ended 30th September 2016.
On June 1st, the Chairman of Sino Biopharmaceutical (OTCPK:SBMFF) entered into an agreement with the company which gives him control of Beijing Tide, a subsidiary of the company, which is set to list on the A-share market. Had control of the company stayed at the Company, there would certainly be much more value to a potential acquirer.
Companies engaged in vaccine development, research, MAB, and liquid biopsy set to gain as they develop products to tackle deadly disease
The Goldman Sachs Asia Equity Fund Class A (GSAGX) has had a terrible 2016 so far. It stands dead last among its nine peers in this review YTD (year-to-date) in 2016. Except for the one-year period, in which it ranks sixth, the fund has placed among the bottom two funds across periods.
Over the six months ended 31st March 2016, the Company's return on net assets was 9.0% and the return to Ordinary shareholders 8.3%, reflecting a widening of the Company's discount over the period. The Company underperformed its benchmark, the MSCI Asia ex Japan Index, which returned 11.4%.
Energy and utilities sectors to bear brunt of sell-off as investors pull out on concerns over US interest rates and weak commodities prices
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton